Complete Response Rate News Today

Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.

Replimune Group's experimental combination therapy for skin cancer, involving its lead therapy RP1 and Regeneron's Libtayo, failed to significantly re

/PRNewswire/ -- OncoBeta® GmbH, a medical device company specialised in innovative epidermal radioisotope therapies, has confirmed the phase IV international...

– Zandelisib Demonstrated 70.3% Objective Response Rate and 35.2% Complete Response Rate –– 87.5% of Responses Achieved in First Two Cycles of Therapy, 75% of CRs in First Four Cycles –– 9.9% of Patients Discontinued Therapy Due to a Drug Related Adverse Event –– 83% Reported Grade 3 Adverse Events of Special Intere...

/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...

/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

- XPOVIO® (selinexor) approvals received in Mainland China, Australia, South Korea and Singapore, expect Hong Kong and Taiwan in remainder of 2022. - 2021 Revenue of RMB28.8 million, Named Patient Program paving way for strong commercial launch in 2022. - Broad and deep clinical program of 18 studies, including 5 registrational studies, ongoing across multiple regions. - Strong cash,...

/PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell...

/PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell...